Eli Lilly (LLY) Return on Capital Employed (2009 - 2026)

Eli Lilly has reported Return on Capital Employed for 18 years, with the latest figure at 42.94% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 806.0% year-over-year to 42.94%; the trailing twelve-month figure through Mar 2026 stood at 42.94% (up 806.0% YoY), and the FY2025 full-year result was 48.39%, up 1075.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 42.94%, up from 37.22% in the prior quarter.
• The five-year high for Return on Capital Employed was 42.94% in Q1 2026, with the low at 20.0% in Q1 2023.
• Historically, Return on Capital Employed has averaged 30.19% across 5 years, with a median of 28.23% in 2024.
• Annual changes were most pronounced in 2023 — Return on Capital Employed sank 575 bps — and 2025, when it soared 1002 bps.
• Eli Lilly's Return on Capital Employed stood at 25.64% in 2022, then gained by 19 bps to 30.47% in 2023, then climbed by 9 bps to 33.16% in 2024, then gained by 12 bps to 37.22% in 2025, then climbed by 15 bps to 42.94% in 2026.
• The last three Return on Capital Employed figures came in at 42.94% (Q1 2026), 37.22% (Q4 2025), and 37.83% (Q3 2025), per Business Quant data.